Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ofatumumab
Find trials that include:  Any drugs shown
Results 1-23 of 23 for your search:
Start Over
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 113676, NCI-2012-01195, NCT01200589
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-07, NCI-2014-00977, NCT02004522
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-12, NCI-2014-02041, NCT02049515
Bendamustine Hydrochloride, Ofatumumab, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11D.404, NCI-2011-03434, 2011-61, NCT01458366
Ofatumumab and Prednisone in Treating Patients With Chronic Graft-Versus-Host Disease
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: MCC-17071, NCI-2012-02451, 00008286, NCT01680965
Ofatumumab in Treating Patients with High-Risk, Previously Untreated, Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0241, NCI-2011-00745, NCT01243190
Ofatumumab and Bendamustine Hydrochloride with or without Bortezomib in Treating Patients with Untreated Follicular Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 50904, NCI-2011-02625, CDR0000694298, NCT01286272
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 114612, NCI-2011-01815, OFB114612, NCT01294579
Ofatumumab, Combination Chemotherapy, and Filgrastim Before Stem Cell Collection in Treating Patients with Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 2009-0796, NCI-2011-01068, NCT01329900
Alemtuzumab and Ofatumumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 10H06, NCI-2011-00514, 114699, 114813, 2010-024389-23, STU00044115, NCT01361711
Combination Chemotherapy and Ofatumumab in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2010-0708, NCI-2011-01061, NCT01363128
Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II
Type: Treatment
Age: 65 and over
Trial IDs: 2011-0520, NCI-2013-00726, 15857, NCCN-006, NCT01444716
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-16622, NCI-2012-00066, GSK OFT114879, RV-CLL-PI-0560, NCT01496976
Ofatumumab and Fresh Frozen Plasma in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#232, NCI-2013-00118, 333961, OFT116066, NCT01716208
Idelalisib and Ofatumumab in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-309, NCI-2014-01554, IN-US-312-1237, NCT02135133
Bendamustine Hydrochloride, Pentostatin, and Ofatumumab in Treating Patients with Previously Treated Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11P.166, NCI-2011-02341, 2011-23, NCT01352312
Recombinant Human IL-18 and Ofatumumab after PBSCT for Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IUCRO-0397, NCI-2013-00003, NCT01768338
Ofatumumab with or without Bendamustine Hydrochloride in Treating Patients with Mantel Cell Lymphoma That Are Ineligible for Stem Cell Transplant
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 11-050, NCI-2011-03128, NCT01437709
Start Over